Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products within the two business areas Chromatography and Drug Development.
The company’s vision is to contribute to better and cheaper medicine through porous silica.
In Chromatography, the aim is to make diabetes drugs available to more patients by providing products that can lower the production costs at the manufacturers.
In Drug Development the company’s platform for inhalation is developed to give patients with severe lung diseases access to new or improved treatments.
Better and cheaper medicine through porous silica.
We aim to make diabetes drugs available to more patients by providing products that can lower the production costs at the manufacturers.
We develop our inhalation platform to give patients with severe lung diseases access to new or improved treatments.
Within the Chromatography business area, Nanologica works to establish a rapidly growing, sustainable and profitable business by providing products for the analysis and purification of substances, with a focus on peptides and diabetes drugs. Once large-scale production of silica has been established, the company intends to conduct sales directly and together with partners on all major markets – India, China, the US and Europe.
In the Drug Development business area, Nanologica focuses on inhalation as a route of administration. The ambition is to advance the development in the field of inhalation, by providing a unique platform for local delivery of medicines to the lung and thereby creating long-term values both with own products, as well as together with partners. Proving the technology in own projects is expected to increase the possibility of lucrative partner projects. In the short term, the goal is to identify drug candidates for clinical development, with the long-term goal of putting products based on the company’s technology on the market to substantially improve the quality of life for patients with lung diseases.
Nanologica operates from the headquarters in Södertälje, Sweden and Nanologica’s stock (NICA) is listed on Nasdaq Stockholm Main Market.